Trial Profile
The international, non-interventional, Coptimze trial of glatiramer acetate injection in relapsing-remitting multiple sclerosis.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Sep 2015
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms Coptimize
- Sponsors Teva Pharmaceutical Industries
- 15 Apr 2011 Preliminary results have been presented at AAN-2011 according to a Teva Pharmaceutical Industries media release; results were also reported in the media release.
- 15 Apr 2011 New trial record